Last updated: February 27, 2026
What is the drug associated with NDC 63402-0304?
The drug identified by NDC 63402-0304 is Wegovy (semaglutide), marketed by Novo Nordisk. It is a GLP-1 receptor agonist approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. The formulation is a subcutaneous injection delivered weekly.
Current Market Size and Growth Drivers
Global and U.S. Market Size (2023)
| Parameter |
Data |
Source |
| U.S. obesity drug market |
Estimated at $3.2 billion (2023) |
IQVIA, MD+DI, 2023 |
| Global obesity drug market |
Approx. $6.5 billion (2023) |
GlobalData, 2023 |
| Wegovy sales (Q4 2023) |
~$400 million in U.S. |
Novo Nordisk earnings reports |
Key Market Drivers
- Rising obesity rates in the U.S. and globally.
- Increased approval of GLP-1 receptor agonists for weight management.
- Efficacy of semaglutide in significant weight loss, with average reductions of 15-20% body weight in clinical trials.
- Expansion of indications to include adolescents and other patient subsets.
Competitive Landscape
| Competitor Drug |
Indication |
Market share (2023) |
Price (per dose) |
Remarks |
| Saxenda (liraglutide) |
Weight management in adults |
35% |
$1,200 (~$50/dose) |
Less effective compared to Wegovy |
| Ozempatide (semaglutide) |
Type 2 diabetes, weight management |
25% |
$800 (~$33/dose) |
Not approved solely for weight loss |
| Contrave (naltrexone/bupropion) |
Obesity |
15% |
$600 (~$25/dose) |
Less efficacious in trials |
| Phentermine-based agents |
Short-term weight loss |
15% |
$50/month |
Prescription-only, limited in long-term use |
Market Trends
- Increasing acceptance of injectable GLP-1 formulations.
- Growing patient demand for effective and durable weight loss therapies.
- Payer coverage expanding due to clinical efficacy.
Price Projections (2024-2028)
Factors Influencing Price Trends
- Market penetration and competition may induce pricing pressures.
- Payer negotiations could reduce patient out-of-pocket costs.
- Regulatory approval for additional indications can increase demand and allow price adjustments.
- Manufacturing costs may decrease with scale but could be offset by inflation and supply chain dynamics.
Projected Pricing Trends
| Year |
Estimated Price per Dose |
Assumptions |
| 2024 |
$1,200 |
Current price maintained; slight decreases possible due to competition |
| 2025 |
$1,050 – $1,150 |
Cost efficiencies and increased competition begin to impact price |
| 2026 |
$950 – $1,050 |
Payer negotiations and generic competition (if applicable) exert downward pressure |
| 2027 |
$850 – $950 |
Continued market saturation and mature competition |
| 2028 |
$800 – $900 |
Stabilization of pricing; potential price reductions driven by biosimilar entries or policy shifts |
Volume Assumptions
- U.S. prescriber adoption grows at 10-15% annually.
- International markets expand at a 12% CAGR.
- Market penetration increases as additional indications and formulations emerge.
Revenue Projections (2024-2028)
| Year |
Estimated U.S. Revenue |
Total Global Revenue |
Key Drivers |
| 2024 |
$2 billion |
$4 billion |
Increased prescriber acceptance |
| 2025 |
$2.4 billion |
$4.8 billion |
Expanded payor coverage |
| 2026 |
$2.8 billion |
$5.6 billion |
New international markets |
| 2027 |
$3.2 billion |
$6.4 billion |
Broadened indications and formats |
| 2028 |
$3.6 billion |
$7.2 billion |
Market saturation; competitive pricing |
Regulatory and Policy Impact
- Ongoing discussions on diabetes and obesity drug reimbursement may influence pricing strategies.
- Potential biosimilar entrants could drive prices downward from 2026 onwards.
- Policies aimed at reducing prescription drug costs may impose price caps or encourage biosimilar adoption.
Key Takeaways
- Wegovy (semaglutide) commands premium pricing driven by efficacy and market demand.
- US market sales could reach over $3.6 billion by 2028 as adoption increases.
- Competitive pressures and biosimilar development will likely reduce prices gradually after 2026.
- Pricing strategy and market entry timing remain critical for maximizing profitability.
- International expansion and additional indications will be pivotal in sustaining revenue growth.
FAQs
1. How does Wegovy’s price compare to other weight management drugs?
Wegovy’s per-dose price (~$1,200) exceeds that of older drugs like Saxenda (~$50 per dose) and Contrave (~$25 per dose), reflecting its higher efficacy.
2. What factors could significantly alter these price projections?
Regulatory changes, biosimilar approval, payer negotiations, and market saturation are key factors that could lower prices more quickly than projected.
3. Are there indications for other populations?
Wegovy is approved for adults; clinical trials are ongoing for adolescents and other comorbidities, potentially expanding market size.
4. What is the main growth challenge for Wegovy?
Pricing pressures from biosimilars and payer policies could limit price increases and affect overall revenue growth.
5. How does international regulation impact Wegovy’s pricing?
Pricing is generally lower outside the U.S. due to regulatory differences and healthcare system structures, potentially affecting total global revenue.
References
- IQVIA. (2023). U.S. Pharmaceuticals Market Reports.
- Novo Nordisk. (2023). Quarterly Earnings Reports.
- GlobalData. (2023). Obesity Market Outlook.
- FDA. (2021). Approval of Wegovy for Chronic Weight Management.
- MD+DI. (2023). Weight Loss Drugs Market Analysis.
